Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2018

View Archived Issues

Pfizer reflects on milestones of fourth quarter 2017

EMA accepts fremanezumab MAA

Celgene begins tender offer for Juno Therapeutics

Takeda describes novel Toll-like receptor 4 antagonists

SYT7 identifies gastric cancer with hepatic metastasis

Novo Nordisk updates events of fourth quarter 2017

Astellas Pharma, Pfizer support research into role of AR in breast cancer

Shanghai Synergy initiates phase I/II study in China with hypidone in major depressive disorder

Phase III AEGIS-CKD study of Feraccru does not meet primary endpoint

NEOLAP trial interim results presented for patients with LAPC

A1M Pharma seeks Swedish clearance to begin phase I study of ROSgard

ReViral reports promising outcome from phase IIa challenge study of RV-521 in RSV

Tetra Bio-Pharma cleared to begin phase III trial of PPP-001 in patients with terminal cancer

Amgen discovers new sodium channel blockers

Novel beta-glucuronidase inhibitors patented by UNC Chapel Hill

Latvian Institute of Organic Synthesis presents seleopheno[h]chromene derivatives

PTGDR2 antagonists patented by Jiangsu Chia Tai Tianqing Pharmaceutical, Medshine Discovery

High rate of response seen with nivolumab/nab-paclitaxel treatment in PDAC

Asahi Kasei launches Kevzara in Japan

FDA grants orphan drug designation to Hanmi's LAPS glucagon analogue

Vancomycin-based vancapticins overcome Gram-positive bacterial resistance

Palatin initiates phase I study of melanocortin MC1 receptor agonist PL-8177

CtBP2 and CD44 found useful for risk stratification of GIST patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...